Canada Biotechnology & Medical Research

Definium Therapeutics Inc (DFTX)

Track

Over the past 90 days, Definium Therapeutics Inc. insiders have executed 10 transactions, all of which were sales totaling approximately $5.07 million. Key executives, including the CEO, CFO, and Chief Medical Officer, participated in these planned and proposed divestments. This activity follows a period where the stock price experienced a 91.1% increase.
Ticker: DFTX Exchange: NSM
Preparing chart...
Download chart Copy chart image Copy link Share to X Share


• Purchase • Sale • Planned purchase • Planned sale Net purchase Net sale Buy signal Sell signal Earnings
No insider activity signals detected

Insider trades have not triggered unusual activity signals for this company.

Top insiders
Trades
Barrow Robert
Chief Executive Officer
1 sale — total 1,315,236 USD
Planned sale 25 Jun 2026
Value US$1,564,457.62 | Price 304.96 | Shares 40,501
Planned sale 25 Jun 2026
Value US$4,187,415.79 | Price 40.51 | Shares 94,717
Planned sale 25 Jun 2026
Value US$135,675.39 | Price 45.03 | Shares 3,013
Planned sale 25 Jun 2026
Value US$451,876.05 | Price 45.03 | Shares 10,035
Planned sale 25 Jun 2026
Value US$585,750.24 | Price 45.03 | Shares 13,008
Proposed sale 25 Jun 2026
Value US$120,786.71 | Price 42.13 | Shares 2,867
Proposed sale 25 Jun 2026
Value US$548,027.04 | Price 42.13 | Shares 13,008
Proposed sale 25 Jun 2026
Value US$126,937.69 | Price 42.13 | Shares 3,013
Proposed sale 25 Jun 2026
Value US$422,774.55 | Price 42.13 | Shares 10,035
Proposed sale 25 Jun 2026
Value US$1,230,533.04 | Price 42.13 | Shares 29,208
Planned sale 25 Mar 2026
Value US$148,092.46 | Price 18.47 | Shares 8,018
Planned sale 25 Mar 2026
Value US$197,665.94 | Price 18.47 | Shares 10,702
Planned sale 25 Mar 2026
Value US$451,240.57 | Price 18.47 | Shares 24,431
Proposed sale 25 Mar 2026
Value US$148,092.46 | Price 18.47 | Shares 8,018
Proposed sale 25 Mar 2026
Value US$451,240.57 | Price 18.47 | Shares 24,431
Proposed sale 25 Mar 2026
Value US$197,665.94 | Price 18.47 | Shares 10,702
Proposed sale 26 Dec 2025
Value US$73,622.64 | Price 13.15 | Shares 5,600
Proposed sale 26 Dec 2025
Value US$148,244.44 | Price 13.15 | Shares 11,276
Proposed sale 26 Dec 2025
Value US$339,071.70 | Price 13.15 | Shares 25,791
Planned sale 26 Dec 2025
Value US$339,071.70 | Price 13.15 | Shares 25,791
Planned sale 26 Dec 2025
Value US$148,244.44 | Price 13.15 | Shares 11,276
Planned sale 26 Dec 2025
Value US$73,622.64 | Price 13.15 | Shares 5,600
Planned sale 25 Sep 2025
Value US$75,268.08 | Price 9.77 | Shares 7,704
Planned sale 25 Sep 2025
Value US$110,186.06 | Price 9.77 | Shares 11,278
Planned sale 25 Sep 2025
Value US$252,036.69 | Price 9.77 | Shares 25,797
Proposed sale 25 Sep 2025
Value US$110,216.51 | Price 9.77 | Shares 11,278
Proposed sale 25 Sep 2025
Value US$75,288.88 | Price 9.77 | Shares 7,704
Proposed sale 25 Sep 2025
Value US$252,106.34 | Price 9.77 | Shares 25,797
Planned sale 25 Jun 2025
Value US$180,138.80 | Price 6.80 | Shares 26,491
Planned sale 25 Jun 2025
Value US$53,366.40 | Price 6.80 | Shares 7,848
Planned sale 25 Jun 2025
Value US$78,138.80 | Price 6.80 | Shares 11,491
Proposed sale 25 Jun 2025
Value US$53,387.59 | Price 6.80 | Shares 7,848
Proposed sale 25 Jun 2025
Value US$78,169.83 | Price 6.80 | Shares 11,491
Proposed sale 25 Jun 2025
Value US$180,210.33 | Price 6.80 | Shares 26,491
Planned sale 25 Mar 2025
Value US$44,322.24 | Price 6.74 | Shares 6,576
Planned sale 25 Mar 2025
Value US$15,818.78 | Price 6.74 | Shares 2,347
Planned sale 25 Mar 2025
Value US$46,074.64 | Price 6.74 | Shares 6,836
Planned sale 25 Mar 2025
Value US$142,941.92 | Price 6.74 | Shares 21,208
Proposed sale 25 Mar 2025
Value US$44,303.83 | Price 6.74 | Shares 6,576
Proposed sale 25 Mar 2025
Value US$15,812.21 | Price 6.74 | Shares 2,347
Proposed sale 25 Mar 2025
Value US$142,882.54 | Price 6.74 | Shares 21,208
Proposed sale 25 Mar 2025
Value US$46,055.50 | Price 6.74 | Shares 6,836
Planned sale 26 Dec 2024
Value US$49,357.49 | Price 7.43 | Shares 6,643
Planned sale 26 Dec 2024
Value US$141,957.58 | Price 7.43 | Shares 19,106
Planned sale 26 Dec 2024
Value US$33,576.17 | Price 7.43 | Shares 4,519
Planned sale 26 Dec 2024
Value US$16,888.39 | Price 7.43 | Shares 2,273
Proposed sale 26 Dec 2024
Value US$141,978.60 | Price 7.43 | Shares 19,106
Proposed sale 26 Dec 2024
Value US$33,581.14 | Price 7.43 | Shares 4,519
Proposed sale 26 Dec 2024
Value US$49,364.80 | Price 7.43 | Shares 6,643
Proposed sale 26 Dec 2024
Value US$16,890.89 | Price 7.43 | Shares 2,273
Buy 5 Dec 2024
Value US$17,925.00 | Price 7.17 | Shares 2,500
Proposed sale 25 Sep 2024
Value US$26,486.79 | Price 5.98 | Shares 4,430
Proposed sale 25 Sep 2024
Value US$41,081.43 | Price 5.98 | Shares 6,871
Proposed sale 25 Sep 2024
Value US$118,210.02 | Price 5.98 | Shares 19,771
Planned sale 25 Sep 2024
Value US$118,230.58 | Price 5.98 | Shares 19,771
Planned sale 25 Sep 2024
Value US$41,088.58 | Price 5.98 | Shares 6,871
Planned sale 25 Sep 2024
Value US$26,491.40 | Price 5.98 | Shares 4,430
Planned sale 25 Sep 2024
Value US$14,064.96 | Price 5.98 | Shares 2,352
Buy 23 Aug 2024
Value US$20,930.00 | Price 5.98 | Shares 3,500
Buy 20 Aug 2024
Value US$3,060.00 | Price 6.12 | Shares 500
Buy 19 Aug 2024
Value US$3,155.00 | Price 6.31 | Shares 500
Proposed sale 25 Jun 2024
Value US$128,978.90 | Price 7.22 | Shares 17,854
Proposed sale 25 Jun 2024
Value US$113,122.03 | Price 7.22 | Shares 15,659
Proposed sale 25 Jun 2024
Value US$50,026.82 | Price 7.22 | Shares 6,925
Planned sale 25 Jun 2024
Value US$128,905.88 | Price 7.22 | Shares 17,854
Planned sale 25 Jun 2024
Value US$49,998.50 | Price 7.22 | Shares 6,925
Planned sale 25 Jun 2024
Value US$113,057.98 | Price 7.22 | Shares 15,659
Planned sale 25 Mar 2024
Value US$156,930.50 | Price 9.50 | Shares 16,519
Planned sale 25 Mar 2024
Value US$62,491.00 | Price 9.50 | Shares 6,578
Proposed sale 25 Mar 2024
Value US$62,468.83 | Price 9.50 | Shares 6,578
Proposed sale 25 Mar 2024
Value US$156,874.83 | Price 9.50 | Shares 16,519
Proposed sale 1 Mar 2024
Value US$39,400.00 | Price 3.94 | Shares 10,000
Proposed sale 26 Dec 2023
Value US$48,072.81 | Price 3.63 | Shares 13,237
Proposed sale 26 Dec 2023
Value US$24,601.14 | Price 3.63 | Shares 6,774
Proposed sale 26 Dec 2023
Value US$20,526.37 | Price 3.63 | Shares 5,652
Abbreviations B: Buy, S: Sell, PP: Planned purchase, PlS: Planned sale, PrS: Proposed sale, O: Option / Other
Notification date Transaction date B/S Transaction type Insider and/or position Nb. shares
Price
Value 		Number of shares Price Value Details
2026-06-26 2026-06-25 PlS Planned sale
Barrow Robert

Chief Executive Officer

Executive Director
40,501 -22.4%
304.96
US$1,564,458 		40,501 -22.4% 304.96 US$1,564,458
2026-06-26 2026-06-25 PlS Planned sale
Wiley Matthew T.

Chief Commercial Officer

Officer
94,717 +19.2%
40.51
US$4,187,416 		94,717 +19.2% 40.51 US$4,187,416
2026-06-26 2026-06-25 PlS Planned sale
Roberts Brandi

Chief Financial Officer

Officer
39,840 +25.7%
27.52
US$3,265,259 		39,840 +25.7% 27.52 US$3,265,259
2026-06-26 2026-06-25 PlS Planned sale
Karlin Daniel

Chief Medical Officer

Officer
10,035 -2.0%
45.03
US$451,876 		10,035 -2.0% 45.03 US$451,876
2026-06-26 2026-06-25 PlS Planned sale
3.6
Sullivan Mark

Chief Legal Officer

Officer
13,008 -3.9%
45.03
US$585,750 		13,008 -3.9% 45.03 US$585,750
2026-06-25 2026-06-25 PrS Proposed sale
MATTHEW THOMAS WILEY

Officer

Officer
2,867
42.13
US$120,787 		2,867 42.13 US$120,787
2026-06-25 2026-06-25 PrS Proposed sale
3.6
MARK SULLIVAN

Officer

Officer
13,008
42.13
US$548,027 		13,008 42.13 US$548,027
2026-06-25 2026-06-25 PrS Proposed sale
BRANDI ROBERTS

Officer

Officer
3,013
42.13
US$126,938 		3,013 42.13 US$126,938
2026-06-25 2026-06-25 PrS Proposed sale
DANIEL ROLLINGS KARLIN

Officer

Officer
10,035
42.13
US$422,775 		10,035 42.13 US$422,775
2026-06-25 2026-06-25 PrS Proposed sale
ROBERT B BARROW

Officer; Director

Executive Director
29,208
42.13
US$1,230,533 		29,208 42.13 US$1,230,533
2026-03-26 2026-03-25 PlS Planned sale
Karlin Daniel

Chief Medical Officer

Officer
8,018 -1.9%
18.47
US$148,092 		8,018 -1.9% 18.47 US$148,092
2026-03-26 2026-03-25 PlS Planned sale
3.6
Sullivan Mark

Chief Legal Officer

Officer
10,702 -3.8%
18.47
US$197,666 		10,702 -3.8% 18.47 US$197,666
2026-03-26 2026-03-25 PlS Planned sale
Barrow Robert

Chief Executive Officer

Executive Director
24,431 -3.1%
18.47
US$451,241 		24,431 -3.1% 18.47 US$451,241
2026-03-25 2026-03-25 PrS Proposed sale
DANIEL ROLLINGS KARLIN

Officer

Officer
8,018
18.47
US$148,092 		8,018 18.47 US$148,092
2026-03-25 2026-03-25 PrS Proposed sale
ROBERT B BARROW

Officer; Director

Executive Director
24,431
18.47
US$451,241 		24,431 18.47 US$451,241
2026-03-25 2026-03-25 PrS Proposed sale
3.6
MARK SULLIVAN

Officer

Officer
10,702
18.47
US$197,666 		10,702 18.47 US$197,666
2025-12-29 2025-12-26 PrS Proposed sale
Karlin, Dan

Officer

Officer
5,600
13.15
US$73,623 		5,600 13.15 US$73,623
2025-12-29 2025-12-26 PrS Proposed sale
3.6
Sullivan, Mark

Officer

Officer
11,276
13.15
US$148,244 		11,276 13.15 US$148,244
2025-12-29 2025-12-26 PrS Proposed sale
Barrow, Robert

Officer, Director

Executive Director
25,791
13.15
US$339,072 		25,791 13.15 US$339,072
2025-12-29 2025-12-26 PlS Planned sale
Barrow Robert

Chief Executive Officer

Executive Director
25,791 -3.2%
13.15
US$339,072 		25,791 -3.2% 13.15 US$339,072
2025-12-29 2025-12-26 PlS Planned sale
3.6
Sullivan Mark

Chief Legal Officer

Officer
11,276 -3.8%
13.15
US$148,244 		11,276 -3.8% 13.15 US$148,244
2025-12-29 2025-12-26 PlS Planned sale
Karlin Daniel

Chief Medical Officer

Officer
5,600 -1.3%
13.15
US$73,623 		5,600 -1.3% 13.15 US$73,623
2025-09-26 2025-09-25 PlS Planned sale
Karlin Daniel

Chief Medical Officer

Officer
7,704 -1.8%
9.77
US$75,268 		7,704 -1.8% 9.77 US$75,268
2025-09-26 2025-09-25 PlS Planned sale
3.6
Sullivan Mark

Chief Legal Officer

Officer
11,278 -3.7%
9.77
US$110,186 		11,278 -3.7% 9.77 US$110,186
2025-09-26 2025-09-25 PlS Planned sale
Barrow Robert

Chief Executive Officer

Executive Director
25,797 -3.1%
9.77
US$252,037 		25,797 -3.1% 9.77 US$252,037
2025-09-25 2025-09-25 PrS Proposed sale
3.6
MARK SULLIVAN

Officer

Officer
11,278
9.77
US$110,217 		11,278 9.77 US$110,217
2025-09-25 2025-09-25 PrS Proposed sale
DANIEL ROLLINGS KARLIN

Officer

Officer
7,704
9.77
US$75,289 		7,704 9.77 US$75,289
2025-09-25 2025-09-25 PrS Proposed sale
ROBERT B BARROW

Officer; Director

Executive Director
25,797
9.77
US$252,106 		25,797 9.77 US$252,106
2025-06-26 2025-06-25 PlS Planned sale
Barrow Robert

Chief Executive Officer

Executive Director
26,491 -3.1%
6.80
US$180,139 		26,491 -3.1% 6.80 US$180,139
2025-06-26 2025-06-25 PlS Planned sale
Karlin Daniel

Chief Medical Officer

Officer
7,848 -1.8%
6.80
US$53,366 		7,848 -1.8% 6.80 US$53,366
2025-06-26 2025-06-25 PlS Planned sale
3.6
Sullivan Mark

Chief Legal Officer

Officer
11,491 -3.6%
6.80
US$78,139 		11,491 -3.6% 6.80 US$78,139
2025-06-25 2025-06-25 PrS Proposed sale
DANIEL ROLLINGS KARLIN

Officer

Officer
7,848
6.80
US$53,388 		7,848 6.80 US$53,388
2025-06-25 2025-06-25 PrS Proposed sale
3.6
MARK SULLIVAN

Officer

Officer
11,491
6.80
US$78,170 		11,491 6.80 US$78,170
2025-06-25 2025-06-25 PrS Proposed sale
ROBERT B BARROW

Officer; Director

Executive Director
26,491
6.80
US$180,210 		26,491 6.80 US$180,210
2025-03-26 2025-03-25 PlS Planned sale
3.6
Sullivan Mark

Chief Legal Officer

Officer
6,576 -2.0%
6.74
US$44,322 		6,576 -2.0% 6.74 US$44,322
2025-03-26 2025-03-25 PlS Planned sale
Liao Carrie

Chief Accounting Officer

Officer
2,347 -1.6%
6.74
US$15,819 		2,347 -1.6% 6.74 US$15,819
2025-03-26 2025-03-25 PlS Planned sale
Karlin Daniel

Chief Medical Officer

Officer
6,836 -1.5%
6.74
US$46,075 		6,836 -1.5% 6.74 US$46,075
2025-03-26 2025-03-25 PlS Planned sale
Barrow Robert

Chief Executive Officer

Executive Director
21,208 -2.4%
6.74
US$142,942 		21,208 -2.4% 6.74 US$142,942
2025-03-25 2025-03-25 PrS Proposed sale
3.6
MARK SULLIVAN

Officer

Officer
6,576
6.74
US$44,304 		6,576 6.74 US$44,304
2025-03-25 2025-03-25 PrS Proposed sale
CARRIE LIAO

Officer

Officer
2,347
6.74
US$15,812 		2,347 6.74 US$15,812
2025-03-25 2025-03-25 PrS Proposed sale
ROBERT B BARROW

Officer; Director

Executive Director
21,208
6.74
US$142,883 		21,208 6.74 US$142,883
2025-03-25 2025-03-25 PrS Proposed sale
DANIEL ROLLINGS KARLIN

Officer

Officer
6,836
6.74
US$46,056 		6,836 6.74 US$46,056
2024-12-27 2024-12-26 PlS Planned sale
Karlin Dan

Chief Medical Officer

Officer
6,643 -1.9%
7.43
US$49,357 		6,643 -1.9% 7.43 US$49,357
2024-12-27 2024-12-26 PlS Planned sale
Barrow Robert

Chief Executive Officer

Executive Director
19,106 -3.5%
7.43
US$141,958 		19,106 -3.5% 7.43 US$141,958
2024-12-27 2024-12-26 PlS Planned sale
3.6
Sullivan Mark

Chief Legal Officer

Officer
4,519 -2.5%
7.43
US$33,576 		4,519 -2.5% 7.43 US$33,576
2024-12-27 2024-12-26 PlS Planned sale
Liao Carrie

Chief Accounting Officer

Officer
2,273 -2.3%
7.43
US$16,888 		2,273 -2.3% 7.43 US$16,888
2024-12-26 2024-12-26 PrS Proposed sale
ROBERT B BARROW

Officer

Officer
19,106
7.43
US$141,979 		19,106 7.43 US$141,979
2024-12-26 2024-12-26 PrS Proposed sale
3.6
MARK SULLIVAN

Officer

Officer
4,519
7.43
US$33,581 		4,519 7.43 US$33,581
2024-12-26 2024-12-26 PrS Proposed sale
DAN ROLLINGS KARLIN

Officer

Officer
6,643
7.43
US$49,365 		6,643 7.43 US$49,365
2024-12-26 2024-12-26 PrS Proposed sale
CARRIE LIAO

Officer

Officer
2,273
7.43
US$16,891 		2,273 7.43 US$16,891
2024-12-05 2024-12-05 B Purchase
GRYSKA DAVID W
Non-Executive Director
2,500 +14.4%
7.17
US$17,925 		2,500 +14.4% 7.17 US$17,925
2024-09-25 2024-09-25 PrS Proposed sale
3.6
Sullivan, Mark

Officer

Officer
4,430
5.98
US$26,487 		4,430 5.98 US$26,487
2024-09-25 2024-09-25 PrS Proposed sale
Karlin, Dan

Officer

Officer
6,871
5.98
US$41,081 		6,871 5.98 US$41,081
2024-09-25 2024-09-25 PrS Proposed sale
Barrow, Robert

Officer, Director

Executive Director
19,771
5.98
US$118,210 		19,771 5.98 US$118,210
2024-09-25 2024-09-25 PlS Planned sale
Barrow Robert

Chief Executive Officer

Executive Director
19,771 -3.5%
5.98
US$118,231 		19,771 -3.5% 5.98 US$118,231
2024-09-25 2024-09-25 PlS Planned sale
Karlin Dan

Chief Medical Officer

Officer
6,871 -2.0%
5.98
US$41,089 		6,871 -2.0% 5.98 US$41,089
2024-09-25 2024-09-25 PlS Planned sale
3.6
Sullivan Mark

Chief Legal Officer

Officer
4,430 -2.4%
5.98
US$26,491 		4,430 -2.4% 5.98 US$26,491
2024-09-25 2024-09-25 PlS Planned sale
Liao Carrie

Chief Accounting Officer

Officer
2,352 -2.3%
5.98
US$14,065 		2,352 -2.3% 5.98 US$14,065
2024-08-26 2024-08-23 B Purchase
GRYSKA DAVID W
Non-Executive Director
3,500 +25.3%
5.98
US$20,930 		3,500 +25.3% 5.98 US$20,930
2024-08-20 2024-08-20 B Purchase
Barrow Robert

Chief Executive Officer

Executive Director
500 +0.1%
6.12
US$3,060 		500 +0.1% 6.12 US$3,060
2024-08-20 2024-08-19 B Purchase
Barrow Robert

Chief Executive Officer

Executive Director
500 +0.1%
6.31
US$3,155 		500 +0.1% 6.31 US$3,155
2024-06-25 2024-06-25 PrS Proposed sale
3.6
Sullivan, Mark

Officer

Officer
17,854
7.22
US$128,979 		17,854 7.22 US$128,979
2024-06-25 2024-06-25 PrS Proposed sale
Barrow, Robert

Officer, Director

Executive Director
15,659
7.22
US$113,122 		15,659 7.22 US$113,122
2024-06-25 2024-06-25 PrS Proposed sale
Karlin, Dan

Officer

Officer
6,925
7.22
US$50,027 		6,925 7.22 US$50,027
2024-06-25 2024-06-25 PlS Planned sale
3.6
Sullivan Mark

Chief Legal Officer

Officer
17,854 -8.9%
7.22
US$128,906 		17,854 -8.9% 7.22 US$128,906
2024-06-25 2024-06-25 PlS Planned sale
Karlin Dan

Chief Medical Officer

Officer
6,925 -1.9%
7.22
US$49,998 		6,925 -1.9% 7.22 US$49,998
2024-06-25 2024-06-25 PlS Planned sale
Barrow Robert

Chief Executive Officer

Executive Director
15,659 -2.7%
7.22
US$113,058 		15,659 -2.7% 7.22 US$113,058
2024-03-26 2024-03-25 PlS Planned sale
Barrow Robert

Chief Executive Officer

Executive Director
16,519 -2.8%
9.50
US$156,930 		16,519 -2.8% 9.50 US$156,930
2024-03-26 2024-03-25 PlS Planned sale
Karlin Dan

Chief Medical Officer

Officer
6,578 -1.8%
9.50
US$62,491 		6,578 -1.8% 9.50 US$62,491
2024-03-25 2024-03-25 PrS Proposed sale
Dan Karlin

Officer

Officer
6,578
9.50
US$62,469 		6,578 9.50 US$62,469
2024-03-25 2024-03-25 PrS Proposed sale
Robert Barrow

Officer; Director

Executive Director
16,519
9.50
US$156,875 		16,519 9.50 US$156,875
2024-03-01 2024-03-01 PrS Proposed sale
Wiedmann Lindsey Roon

Chief Legal & Sustainability Officer

Officer
10,000
3.94
US$39,400 		10,000 3.94 US$39,400
2023-12-26 2023-12-26 PrS Proposed sale
Robert Barrow

Officer; Director

Executive Director
13,237
3.63
US$48,073 		13,237 3.63 US$48,073
2023-12-26 2023-12-26 PrS Proposed sale
Dan Karlin

Officer

Officer
6,774
3.63
US$24,601 		6,774 3.63 US$24,601
2023-12-26 2023-12-26 PrS Proposed sale
Schond L. Greenway

Officer

Officer
5,652
3.63
US$20,526 		5,652 3.63 US$20,526
Explore more

More insider trading research around Definium Therapeutics Inc

More insider trades in Canada
Similar Healthcare companies with insider activity
More Pharmaceuticals & Medical Research companies with insider activity
More Biotechnology & Medical Research companies with insider activity
Insider trading in North America